美股连续五个交易日下跌，创下年内最大单走跌幅。主要股指在上周跌幅均超过2%。纳斯达克指数结束了连续10周上涨的势头，而道琼工业指数则录得年内第二周下滑。
Gilead Sciences Inc. (GILD), CVS Health Corp. (CVS), Walgreens Boots Alliance Inc. (WBA) and Vodafone Group PLC (VOD) have declined to their three-year lows.
吉利德科学、CVS、Walgreens Boots Alliance和沃达丰集团( Vodafone Group PLC )跌至三年低点。
吉利德科学跌至63.23美元
The price of Gilead Sciences Inc. (GILD) shares declined to $63.23 on March 8, which is 4.6% above the three-year low of $60.32.
吉利德科学（Gilead Sciences）Inc ( GILD )股价3月8日跌至63.23美元，较三年来的低点60.32美元高出4.6%。
Gilead Sciences is an American international pharmaceutical and biotechnology company that develops and commercializes therapeutics. The company focuses primarily on antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C and influenza. Some of the products the company developed include AmBisome, Atripla, Cayston, Emtriva and Flolan.
吉利德科学是一家美国国际制药和生物技术公司，开发和商业化治疗。公司主要专注于用于治疗 HIV、乙肝、丙肝和流感的抗病毒药物。该公司开发的一些产品包括 AmBisome、Atrila、Cayston、Emtriva 和 Flolan。
The company has a market cap of $80.65 billion; its shares were traded around $63.23 with a price-earnings ratio of 15.17 and a price-sales ratio of 3.73. The trailing 12-month dividend yield is 3.61%. The forward dividend yield is 4.03%. Gilead Sciences had an annual average earnings growth of 26.20% over the past 10 years.
该公司的市值为806.5亿美元，股价约为63.23美元，市盈率为15.17倍，市销率为3.73倍。过去12个月的股息收益率为3.61%。远期股息率为4.03%。吉利德科学（Gilead Sciences）过去10年的年均收益增长率为26.20%。
On March 7, the company announced data from two studies supporting the further development of GS-6207, a novel selective inhibitor of HIV-1 caspid function. The drug could potentially be used as part of a long-acting HIV combination therapy. Phase 1 results demonstrated that single doses of the drug achieved sustained concentration levels and were well tolerated, while in vitro data demonstrated the efficacy of the drug against HIV strains resistant to other antiretroviral classes.
3月7日，该公司公布了两项支持进一步开发 GS-6207的研究的数据，这是一种新型的选择性抗 HIV-1 caspid 功能抑制剂。这种药物有可能被用来作为长期作用的 HIV 联合治疗的一部分。第一阶段的结果表明，单一剂量的药物达到了持续的浓度水平，并得到了良好的耐受性，而体外数据显示了该药物对其他抗逆转录病毒药物耐药的 HIV 菌株的疗效。
CVS Health 跌至52.93美元
The price of CVS Health Corp. (CVS) shares declined to $52.93 on March 8, which is 1.6% above the three-year low of $52.10.
CVS Health Corp ( CVS )股价3月8日跌至52.93美元，较52.10美元的三年低点高出1.6%。
CVS Health is an American retail pharmacy and health care company. The business began as a chain of health and beauty stores, but later added pharmacies. The company owns several subsidiaries, including CVS Pharmacy, MinuteClinic, Caremark Rx, Longs Drugs, Omnicare and Navarro Discount Pharmacies.
CVS Health 是一家美国零售药店和医疗保健公司。该业务始于健康美容连锁店，但后来增加了药店。公司拥有 CVS 药房、美诺华诊所、Caremark Rx、Longs Drugs、Omnicare、Navarro Discount Pharmacies 等多家子公司。
The company has a market cap of $68.65 billion; its shares were traded around $52.93 with a price-sales ratio of 0.28. The trailing 12-month dividend yield is 3.79%. The forward dividend yield is 3.82%. CVS had an annual average earnings growth of 7.40% over the past decade.
该公司的市值为686.5亿美元，股价约为52.93美元，销售价格比为0.28。过去12个月的股息收益率为3.79%。远期股息率为3.82%。在过去十年中，CVS 的年均收益增长率为7.40%。
On Feb. 20, CVS reported financial results for fourth-quarter and full-year 2018. Revenue for the quarter increased 12.5% to $54.4 billion. The GAAP diluted loss per share was 37 cents, including a $2.2 billion goodwill impairment charge. Adjusted earnings were $2.14 per share for the quarter. The company also completed its $70 billion acquisition of Aetna.
2月20日，CVS 公布了2018年第四季度和全年的财务业绩。本季度收入增长12.5%，至544亿美元。一般公认会计原则（GAAP）每股摊薄亏损37美分，包括22亿美元的商誉减值费用。本季度调整后每股收益为2.14美元。该公司还完成了对 Aetna 的700亿美元收购。
本文未完，阅读全文请访问www.investank.com
